Cargando…

Population and ultra-deep sequencing for tropism determination are correlated with Trofile ES: genotypic re-analysis of the A4001078 maraviroc study

Detalles Bibliográficos
Autores principales:	Portsmouth, S, Valluri, S, Daeumer, M, Thiele, B, Valdez, H, Lewis, M, Craig, C, Thielen, A, James, I, Demarest, J, Heera, J
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	The International AIDS Society 2010
Materias:	Poster Presentation
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC3112903/ http://dx.doi.org/10.1186/1758-2652-13-S4-P128

Ejemplares similares

First prospective comparison of genotypic vs phenotypic tropism assays in predicting virologic responses to Maraviroc (MVC) in a phase 3 study: MODERN
por: Heera, Jayvant, et al.
Publicado: (2014)

Comparative determination of HIV-1 co-receptor tropism by Enhanced Sensitivity Trofile, gp120 V3-loop RNA and DNA genotyping
por: Prosperi, Mattia CF, et al.
Publicado: (2010)

Maraviroc (MVC) increases CD4+ and CD8+ cells: long-term data from the MVC clinical development program
por: Lazzarin, A, et al.
Publicado: (2010)

Parameters Influencing Baseline HIV-1 Genotypic Tropism Testing Related to Clinical Outcome in Patients on Maraviroc
por: Sierra, Saleta, et al.
Publicado: (2015)

Incidence of ischemic cardiovascular events in the maraviroc clinical development program
por: Portsmouth, S, et al.
Publicado: (2010)

Comparison of phenotypic and genotypic tropism determination in triple-class-experienced HIV patients eligible for maraviroc treatment
por: Vandekerckhove, Linos, et al.
Publicado: (2011)

Genotypic tropism testing by massively parallel sequencing: qualitative and quantitative analysis
por: Däumer, Martin, et al.
Publicado: (2011)

Five-Year Safety Evaluation of Maraviroc in HIV-1–Infected Treatment-Experienced Patients
por: Gulick, Roy M., et al.
Publicado: (2014)

Genotypic tropism testing in proviral DNA to guide maraviroc initiation in aviremic subjects: 48-week analysis of the PROTEST study
por: Garcia, Federico, et al.
Publicado: (2014)

Short-term variation of HIV tropism readouts in the absence of CCR5 antagonists
por: Brumme, CJ, et al.
Publicado: (2010)

Influence of amount and percentage of CXCR4-using virus in predicting week 48 responses to maraviroc in treatment-naïve patients
por: Valdez, H, et al.
Publicado: (2010)

Clinical application of genotypic co-receptor tropism testing from viral RNA and proviral DNA: week 24 analysis of the Berlin maraviroc cohort
por: Obermeier, MJ, et al.
Publicado: (2010)

Phenotypic co-receptor tropism and Maraviroc sensitivity in HIV-1 subtype C from East Africa
por: Siddik, Abu Bakar, et al.
Publicado: (2018)

A7 Co-receptor tropism determined by genotypic assay in HIV-1 non-B subtypes circulating in Cuba: Implications for pathogenesis and Maraviroc resistance
por: Méndez, M, et al.
Publicado: (2019)

Reliable Genotypic Tropism Tests for the Major HIV-1 Subtypes
por: Cashin, Kieran, et al.
Publicado: (2015)

Effects of Maraviroc and Efavirenz on Markers of Immune Activation and Inflammation and Associations with CD4(+) Cell Rises in HIV-Infected Patients
por: Funderburg, Nicholas, et al.
Publicado: (2010)

Once-daily maraviroc versus tenofovir/emtricitabine each combined with darunavir/ritonavir for initial HIV-1 treatment
por: Stellbrink, Hans-Jürgen, et al.
Publicado: (2016)

The Effects of Boceprevir and Telaprevir on the Pharmacokinetics of Maraviroc: An Open-Label, Fixed-Sequence Study in Healthy Volunteers
por: Vourvahis, Manoli, et al.
Publicado: (2014)

HIV-1 Coreceptor Usage Assessment by Ultra-Deep Pyrosequencing and Response to Maraviroc
por: Rodriguez, Christophe, et al.
Publicado: (2015)

Incidence of CXCR4 tropism and CCR5-tropic resistance in treatment-experienced participants receiving maraviroc in the 48-week MOTIVATE 1 and 2 trials
por: Jubb, Becky, et al.
Publicado: (2019)

Pharmacokinetics, Safety and Efficacy of Maraviroc in Treatment-experienced Pediatric Patients Infected With CCR5-Tropic HIV-1
por: Giaquinto, Carlo, et al.
Publicado: (2018)

No Clinical Impact of CYP3A5 Gene Polymorphisms on the Pharmacokinetics and/or Efficacy of Maraviroc in Healthy Volunteers and HIV‐1–Infected Subjects
por: Vourvahis, Manoli, et al.
Publicado: (2018)

Maraviroc in the treatment of HIV infection
por: Ray, Neelanjana
Publicado: (2009)

Use of maraviroc in patients with undetectable viral load: efficacy, tolerance and predictors of viral response in MARAVIROC-cohort study
por: Jesús Pérez Elías, María, et al.
Publicado: (2014)

Efficacy and safety of maraviroc vs. efavirenz in treatment-naive patients with HIV-1: 5-year findings
por: Cooper, David A., et al.
Publicado: (2014)

Genotypic prediction of HIV-1 subtype D tropism
por: Raymond, Stéphanie, et al.
Publicado: (2011)

Maraviroc: the evidence for its potential in the management of HIV
por: Profit, Louise
Publicado: (2007)

Short-term maraviroc exposure, a clinical approach to decide on maraviroc prescription in HIV-1-infected treatment-naïve patients
por: Gonzalez-Serna, Alejandro, et al.
Publicado: (2016)

Implications of maraviroc and/or rapamycin in a mouse model of fragility
por: Pérez-Martínez, Laura, et al.
Publicado: (2020)

A Follow-Up of the Multicenter Collaborative Study on HIV-1 Drug Resistance and Tropism Testing Using 454 Ultra Deep Pyrosequencing
por: St. John, Elizabeth P., et al.
Publicado: (2016)

Immunologic impact of maraviroc in clinical practice of a university hospital
por: Paniagua, S Plata, et al.
Publicado: (2010)

Maraviroc: a review of its use in HIV infection and beyond
por: Woollard, Shawna M, et al.
Publicado: (2015)

Maraviroc-Mediated Lung Protection following Trauma-Hemorrhagic Shock
por: Liu, Fu-Chao, et al.
Publicado: (2016)

High Virologic Failure Rates with Maraviroc-Based Salvage Regimens Among Indian Patients: A Preliminary Analysis—Maraviroc Effectiveness in HIV-1 Subtype C
por: Pujari, Sanjay, et al.
Publicado: (2018)

Genotypic Prediction of Co-receptor Tropism of HIV-1 Subtypes A and C
por: Riemenschneider, Mona, et al.
Publicado: (2016)

Genotypic Prediction of Tropism of Highly Diverse HIV-1 Strains from Cameroon
por: Mbondji-Wonje, Christelle, et al.
Publicado: (2014)

Highly prevalent Russian HIV-1 V3-loop sequence variants are susceptible to maraviroc
por: Lewis, ME, et al.
Publicado: (2021)

A re-evaluation of the archaeological sequences of preclassic Chiapas /
por: Demarest, Arthur Andrew
Publicado: (1976)

HIV entry blocked by maraviroc can cause an overestimation of viral load
por: Sloan, RD, et al.
Publicado: (2010)

Impact of maraviroc on immune restoration in an advanced stage HIV-infected patient
por: Bregigeon, Sylvie, et al.
Publicado: (2010)

Cannot write session to /tmp/vufind_sessions/sess_s4rqd3g0peil2qit4euj0t0v5g